These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36529225)

  • 1. Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia.
    Li F; Lu ZY; Xue YT; Liu Y; Cao J; Sun ZT; Zhang Q; Xu MD; Wang XY; Xu KL; Wu QY
    Int J Biol Macromol; 2023 Feb; 229():247-259. PubMed ID: 36529225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of T875N somatic mutation in the activity, structural stability of JAK2 and the transformation of OCI-AML3 cells.
    Chen C; Li F; Ma MM; Zhang S; Liu Y; Yan ZL; Chen W; Cao J; Zeng LY; Wang XY; Xu KL; Wu QY
    Int J Biol Macromol; 2019 Sep; 137():1030-1040. PubMed ID: 31299252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of R867 and Y613 interaction plays key roles in JAK2 R867Q mutation caused acute leukemia.
    Wu QY; Ma MM; Zhang S; Cao J; Yan ZL; Chen C; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
    Int J Biol Macromol; 2019 Sep; 136():209-219. PubMed ID: 31199972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia.
    Wu QY; Ma MM; Zhang S; Liu Y; Cao J; Yan ZL; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
    Int J Biol Macromol; 2019 Mar; 124():1123-1131. PubMed ID: 30521925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of JAK2 V556F mutation on the JAK2's activity, structural stability and the transformation of Ba/F3 cells.
    Wu QY; Ma MM; Tong YX; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
    Int J Biol Macromol; 2018 Oct; 117():271-279. PubMed ID: 29842959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
    Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
    Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of E627 and R683 interaction is responsible for B-cell acute lymphoblastic leukemia caused by JAK2 R683G(S) mutations.
    Wu QY; Guo HY; Li F; Li ZY; Zeng LY; Xu KL
    Leuk Lymphoma; 2013 Dec; 54(12):2693-700. PubMed ID: 23452118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
    Wu QY; Ma MM; Fu L; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Li F; Wang XY; Xu KL
    Int J Biol Macromol; 2018 Sep; 116():1064-1073. PubMed ID: 29782975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Tong H; Ren Y; Zhang F; Jin J
    Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
    Nagao T; Kurosu T; Umezawa Y; Nogami A; Oshikawa G; Tohda S; Yamamoto M; Miura O
    PLoS One; 2014; 9(1):e84746. PubMed ID: 24404189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research advances in the role of JAK2 mutations in acute leukemia].
    Zhang HY; Zhai XW
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jun; 17(6):644-9. PubMed ID: 26108332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. microRNA-146a Promotes Growth of Acute Leukemia Cells by Downregulating Ciliary Neurotrophic Factor Receptor and Activating JAK2/STAT3 Signaling.
    Wang L; Zhang H; Lei D
    Yonsei Med J; 2019 Oct; 60(10):924-934. PubMed ID: 31538427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphologic and Molecular Characteristics of De Novo AML With
    Hidalgo-López JE; Kanagal-Shamanna R; Medeiros LJ; Estrov Z; Yin CC; Verstovsek S; Konoplev S; Jorgensen JL; Mohammad MM; Miranda RN; Zhao C; Lee J; Zuo Z; Bueso-Ramos CE
    J Natl Compr Canc Netw; 2017 Jun; 15(6):790-796. PubMed ID: 28596259
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
    Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
    Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
    Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
    J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.
    Wan X; Ma Y; McClendon CL; Huang LJ; Huang N
    PLoS Comput Biol; 2013 Apr; 9(4):e1003022. PubMed ID: 23592968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
    Steensma DP; McClure RF; Karp JE; Tefferi A; Lasho TL; Powell HL; DeWald GW; Kaufmann SH
    Leukemia; 2006 Jun; 20(6):971-8. PubMed ID: 16598306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.
    Li F; Guo HY; Wang M; Geng HL; Bian MR; Cao J; Chen C; Zeng LY; Wang XY; Wu QY
    Int J Biol Macromol; 2013 Sep; 60():186-95. PubMed ID: 23748007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
    Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
    Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.